Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 20/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 0.88 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.88 |
| ▸ | HTR2B | P41595 | 1/20 | 0.88 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586957 | 0.94 | HCRTR1 (1.00) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL29912233 | 0.94 | HCRTR1 (1.00) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1778119 | 0.92 | HCRTR2 (0.95) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777087 | 0.87 | HCRTR1 (0.83) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL21018247 | 0.86 | HCRTR1 (0.85) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777979 | 0.84 | HCRTR1 (0.77) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1776844 | 0.84 | HCRTR1 (0.76) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777506 | 0.84 | HCRTR1 (0.81) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777864 | 0.83 | HCRTR1 (0.81) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777860 | 0.83 | HCRTR1 (0.81) | HCRTR1HCRTR2TSPOOPRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12441709-B2 | Therapeutic compounds | INDIVIOR UK LIMITED (GB) | 2025-10-14 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2024-03-07 | — | — | US | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | disclosed |
| EP-3218007-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753398-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 270/4885 |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 270/4885 |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 394/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885TSPO 267/4885 |
| US-12441709-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 270/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885TSPO 267/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 333/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885TSPO 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.